POPULARITY
12 episodes with dmts
17 episodes with dmts
8 episodes with dmts
7 episodes with dmts
7 episodes with dmts
12 episodes with dmts
7 episodes with dmts
5 episodes with dmts
2 episodes with dmts
5 episodes with dmts
8 episodes with dmts
5 episodes with dmts
6 episodes with dmts
5 episodes with dmts
7 episodes with dmts
5 episodes with dmts
40 episodes with dmts
2 episodes with dmts
In this episode, I reflect on recent adventures navigating life with mobility challenges—from enjoying an accessible trip to the ballpark to a spirited night at a hockey game with a friend. I share my growing passion for sled hockey, sparked by a recent intro session, and discuss my ongoing efforts to establish a league right here in Toronto. With an eye on inclusion and sustainability, I talk about the sport's impact, a minor setback with mobility, and what's next on my fitness journey. Join me as I explore the healing, humor, and hope found through adapted sports and community connection.The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com
Multiple Sclerosis (MS) is a complex neurological condition that impacts an estimated 2.8 million people worldwide. This week we explore the science behind MS, treatment options, and the lived experiences of those navigating life with this chronic illness. Multiple Sclerosis (MS) has been called "the disease of 1000 faces" for good reason - it manifests differently in almost every person it affects. Understanding MS: The Science Behind the Disease Dr. Zied Tayeb, neuroscientist and CEO of MyelinZ, explained the fundamental mechanism of MS in terms anyone can understand: "The brain communicates using electrical signals. These signals travel from one neuron to another through axons, which are protected by myelin sheets that help accelerate the transmission of these signals. In MS, the immune system mistakenly attacks these myelin sheets, leading to demyelination.” This disruption in communication between neurons explains why MS symptoms can vary so dramatically - the location of demyelination determines which functions are affected. "It could be the motor cortex, resulting in mobility issues, or the visual cortex, causing problems with vision," Dr. Tayeb noted. While the exact cause of MS remains unknown, researchers have identified several factors that may contribute to its development. According to our panel, MS is significantly more prevalent in women, who represent approximately 65% of MS patients - possibly due to women's more active immune systems making them more susceptible to autoimmune conditions like MS. Geographic distribution also offers clues, with higher rates in regions farther from the equator such as Canada, northern United States, and parts of Europe (with Denmark having a particularly high prevalence). This pattern has led scientists to investigate a potential link with vitamin D deficiency, though studies remain inconclusive. The Patient Experience: Hassan's Journey Few stories illustrate the unpredictable nature of MS better than that of Hassan Nada, entrepreneur, journalist, and self-described "MS warrior." Hassan's first symptom appeared in 2018 when he suddenly lost vision in his right eye while on holiday in Egypt. "I woke up one day, and out of nowhere, my vision was blurry to the point where I thought I was blind," Hassan recalled. Despite seeing an ophthalmologist, his condition went undiagnosed as MS. His vision eventually returned after treatment with corticosteroids. Four years later, after moving to Luxembourg, Hassan experienced sciatic nerve pain and numbness in his lower body. His general practitioner recognized the connection between his previous episode of optic neuritis and his current symptoms, immediately suspecting MS. "She screamed at me and had me go to the ER right away," Hassan shared. After extensive testing, including MRIs, blood tests, and a spinal fluid sample, the diagnosis was confirmed: Hassan had multiple sclerosis. The emotional impact of this diagnosis was profound. "My life changed from that moment onwards, and I went into complete depression," he admitted. But through the unwavering support of his wife and access to modern treatments, Hassan has found ways to adapt and advocate for others with MS. Treatment Approaches: Managing an Incurable Condition While MS currently has no cure, Dr. Tayeb emphasized that it is treatable. "Notwithstanding the fact that MS is incurable, it is treatable," he stated. "The problem is that every patient is different. The trajectory of the progression, diseases, symptoms are different.” Disease-modifying therapies (DMTs) aim to slow the progression of MS by suppressing or modulating the immune system. These treatments vary widely in their administration methods (pills, injections, infusions) and side effect profiles. Hassan's treatment journey illustrates the often challenging process of finding the right approach. After being diagnosed, he was unable to receive his doctor's first-choice treatment due to having a virus that made it dangerous for him. He then tried a pill-based DMT that, despite its high success rate with other patients, didn't work for him. Finally, he found success with a monthly subcutaneous injection called Kesimpta. "Last week I went to the neurologist office depressed," Hassan shared. "I was like, 'I know it didn't work.' She's like, 'No, it actually worked. There are no new lesions. You can now make long-term plans in life.'" Innovative Approaches: The Brain's Virtual Gym Dr. Tayeb and Samaher Garbaya, co-founders of MyelinZ, are taking a different approach to MS management. Their "virtual gym for the brain" uses neurotechnology to promote neuroplasticity - the brain's ability to form new neural connections. "We're trying to promote neuroplasticity in the brain," Dr. Tayeb explained. Their platform uses games to stimulate specific brain regions while measuring brain activity. Using machine learning, they analyze six different digital biomarkers to create personalized brain exercises. This approach draws inspiration from research showing that activities like playing musical instruments or singing can activate certain brain areas, potentially slowing disease progression by strengthening neural pathways. The Role of Support: Community and Family Multiple speakers emphasized that MS affects not just the individual but their entire support network. Anne Leurs, who manages the Multiple Sclerosis Society in Luxembourg, noted that MS typically appears between ages 20-40 - a critical period when people are building careers, starting families, and establishing their adult lives. "It's a very difficult period, this period of diagnosis," Anne observed. "It's a chronicle disease. This means that you will have to live your life on with this disease.” Hassan's experience underscores the crucial role of support systems. "MS either breaks a couple or it makes them the strongest couple in the world," he remarked. When first diagnosed, he told his wife she should leave. "She's like, 'It's because I love you that I'm not leaving, and we're going to make it out of this stronger than ever.'" Five years later, she remains his "backbone," managing his appointments and ensuring he takes his medications. For those without close family support, community organizations like the Multiple Sclerosis Society provide vital resources, information, and connection. Complementary Approaches: The Mind-Body Connection Mariette Lentz, a Luxembourgish soprano who specializes in the Alexander Technique, offered insights into complementary approaches that can help manage MS symptoms and improve quality of life. The Alexander Technique is "a mental technique" focused on "exploring the relationship between our thoughts and our movement," Mariette explained. While not a therapy or cure, it offers tools to help reduce stress and bring the nervous system to a calmer state - particularly valuable for MS patients who often experience anxiety related to their unpredictable symptoms. This, naturally, is a method that can help us all. The Daily Reality Hassan painted a vivid picture of what daily life with MS can entail: "Imagine waking up every day of your life with the worst hangover in the world without having to drink.” Despite this challenge, he maintains a positive outlook and has channeled his experience into advocacy work, connecting with MS communities around the world. "I'm disclosing some personal parts of my life in hopes that it's actually going to benefit people," he explained. Looking Forward: Hope in Research and Community While MS remains incurable, advances in treatment options continue to improve outcomes for patients. From traditional DMTs to innovative approaches like brain-computer interfaces and neuroplasticity training, the landscape of MS management is evolving rapidly. As our conversation demonstrated, the combination of cutting-edge medical science, dedicated healthcare professionals, strong personal support systems, and community resources creates a foundation for living well despite MS. For those navigating the complex journey of MS - whether as patients, family members, or healthcare providers - knowledge and community remain powerful tools. By continuing to share stories like Hassan's and insights from experts like Dr. Tayeb, Samaher Garbaya, Anne Leurs, and Mariette Lentz, we can work toward greater understanding and better support for everyone affected by this challenging condition. https://myelinz.com https://www.msweb.lu/wp/
In this personal episode of The Just MS Show, I share a recent experience of getting stuck in the snow and the unexpected mix of helplessness and gratitude that followed. From the challenges of mobility in winter to the incredible support from strangers who helped push me through, this day was a reminder of the kindness that exists in the world. I also reflect on the services like Wheel-Trans that make life easier for those of us with disabilities in Canada. Sometimes, it's the little things—like a push out of the snow—that remind us not to take life for granted. Tune in for some good vibes and a fresh perspective on gratitude!The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fluid-biomarkers-revolutionizing-ms-diagnosis/32229/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/high-efficacy-dmts-transforming-ms-care/32225/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/balancing-act-immune-reconstitution-vs-immune-suppression/32227/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-pathology-to-practice-the-role-of-inflammation-in-ms-pathology/32228/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/long-term-safety-of-dmts-what-we-know-and-what-we-need-to-know/32226/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/imaging-biomarkers-ms-progression-in-focus/32230/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/personalized-care-for-diverse-ms-populations-special-populations-equal-special-care/32231/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/ms-cognitive-insights-management-diagnostic-and-treatment-strategies/32232/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/brain-health-in-ms-a-comprehensive-approach/32233/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/pros-in-ms-a-new-era-of-patient-centric-care/32234/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.
In this episode of The Just M.S. Show, we delve into the fascinating history of Multiple Sclerosis (MS), a disease that has puzzled and challenged medical professionals for centuries. From early misinterpretations of symptoms to groundbreaking discoveries in neurology and imaging, we explore the journey of understanding MS. Highlights include the story of St. Lidwina, the first documented case of Augustus d'Este, and the pivotal contributions of Jean-Martin Charcot. Learn how advancements in technology, such as MRI, and the development of disease-modifying therapies have transformed the diagnosis and treatment of MS. Join us as we uncover the past, present, and future of this complex disease.---Episode Outline1. IntroductionBrief overview of the episode and why understanding the history of MS matters.2. Early Accounts and ChallengesUnconfirmed historical cases, including St. Lidwina and Augustus d'Este.How the fluctuating and varied symptoms hindered early recognition.3. The Role of Jean-Martin CharcotCharcot's triad and the naming of MS as “la sclérose en plaques.”The clinicopathological approach and its impact on neurology.4. Advancements in PathologyUnderstanding myelin, inflammation, and autoimmune theories.Genetic predisposition and environmental factors (e.g., vitamin D, geography).5. Revolutionizing DiagnosticsMicroscopy and the discovery of myelin.The introduction and evolution of MRI technology.6. The Evolution of TreatmentFrom leeches to steroids and interferons.Modern disease-modifying therapies and their impact on patients' lives.7. Cognitive Aspects of MSThe early recognition and later disregard of cognitive symptoms.Re-emerging focus on mental and cognitive health in MS care.8. The Role of Research OrganizationsThe National MS Society, Sylvia Lawry, and global collaborations.9. Conclusion and ReflectionHow far we've come and the future of MS research and treatment.The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com
CME credits: 0.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-diagnosis-management-and-updates-chairpersons-perspective/26626/ During a satellite symposium at the AHA 2024 Annual Meeting, experts reviewed the role of novel disease-modifying therapies (DMTs) in treating and managing pulmonary hypertension (PH) and the impact of current PH treatments vs novel DMTs. They also discussed how to identify appropriate patients for DMTs and strategies to customize treatment with risk-based assessments. In addition, highlights from the 7th World Symposium in PH were discussed. Tune in to keep up! =
There's an alarming shortage of neurologists in the United States. That shortage makes it hard to be seen by a neurologist and, in some regions of the U.S., you may not even find an MS specialist without having to travel hundreds of miles. The good news is now there's an app for that! Joining me to talk about how an app called BeCare is already changing the game when it comes to MS care is the Chief Medical Officer of BeCareLink, Dr. Charisse Litchman. The FDA has designated Tolebrutinib as a Breakthrough Therapy for the treatment of adults with non-relapsing secondary progressive MS. We're sharing the details. We'll tell you where you can participate in a phase 2 clinical trial that's designed to test the efficacy of Foralumab, an investigational disease-modifying therapy formulated as a nasal spray, among adults with non-relapsing secondary progressive MS. We'll share the details of a report that provides some frustrating data about out-of-pocket costs for MS prescription medications. Dr. Alicyn Magruder reviews the risks and benefits of using off-label medications to manage MS. And we'll share the results of a study that focused on how socioeconomic status impacts disease severity among kids and teens living with MS. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: An app that can tell you if your MS is worsening :22 FDA awards Tolebrutinib Breakthrough Therapy designation 1:04 Phase 2 clinical trial for Foralumab adds 6 additional sites 3:13 Study compares out-of-pocket costs of MS DMTs with meds for other neurologic conditions 5:55 Dr. Alicyn Magruder discusses using off-label medications to manage MS 9:51 Study analyzes the impact of socioeconomic status on disease severity in pediatric-onset MS 15:27 Dr. Charisse Lichtman explains how the BeCare MS app is changing the game and providing an important bridge to better MS care 19:52 Share this episode 30:53 Have you downloaded the free RealTalk MS app? 31:13 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/381 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com RealTalk MS on YouTube https://www.msif.org/webcast-clinical-trials CLINICAL TRIAL: A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients https://clinicaltrials.gov/study/NCT06292923 STUDY: Costs Are Still On the Rise for Commonly Prescribed Branded Neurologic Medications https://neurology.org/doi/10.1212/WNL.0000000000210029 STUDY: Association of Social Determinants of Health with Brain MRI Outcomes in Individuals with Pediatric Onset Multiple Sclerosis https://neurology.org/doi/10.1212/WNL.0000000000210140 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 381 Guests: Dr. Alicyn Magruder, Dr. Charisse Litchman Privacy Policy
It's time to travel across the oceans to talk with today's podcast guest, Cathrin. We'll learn of her journey with MS from her homeland of Sweden. She'll share her story about her: First symptoms as a new mom Questionable and poorly delivered diagnosis Choice of DMTs and failure rates Lifestyle choices that helped relieve her fatigue Career and necessary accommodations Divorce and ensuing stress Journey to find The MS Gym Friendships forged in her Buddy Group Switch to the Wahls diet protocol Physical victories Travel accommodations Flooding threat bucket Need to prioritize work, rest, and chores Advice to the newly diagnosed Ability to show kindness and gratitude to her body The MS Gym Links The MS Gym How Full Is Your Threat Bucket? - Episode
On this podcast, we tend to talk a lot about new technologies, emerging treatments, the most recently approved disease-modifying therapies, and even some DMTs that haven't yet been approved. And in the midst of all that cutting-edge research and evolving science, it's easy to lose sight of the fact that expressive therapies like dance and movement therapy, music therapy, and art therapy have all been shown to help promote self-efficacy, emotional well-being, and motor control in people living with MS. Dr. Francois Bethoux joins me on today's episode to discuss the benefits of integrating dance and movement therapy, music therapy, and art therapy into your treatment plan to help manage your MS symptoms and enhance your well-being. November is National Family Caregivers Month, and we're sharing a neat piece of tech that can not only make life easier for MS caregivers but can make life better for their care recipients, as well. CEO Costin Tuculescu introduces us to his company's new device, OnScreen. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Adding expressive therapies to your MS treatment plan :22 OnScreen CEO Costin Tuculescu explains how OnScreen can help people with MS and their caregivers 1:34 Dr. Francoi Bethoux discusses the benefits of dance therapy, music therapy, and art therapy for people living with MS 17:45 Share this episode 31:47 Have you downloaded the free RealTalk MS app? 32:06 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/376 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com OnScreen https://onscreeninc.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 376 Guests: Costin Tuculescu and Dr. Francois Bethoux Privacy Policy
Welcome to Living Well with MS, the podcast that empowers you to take control of your health and wellbeing. Today we're thrilled to welcome back Dr Aaron Boster as our guest! Dr Boster is a board-certified Neurologist specialising in Multiple Sclerosis. He is a frequent guest on Living Well with MS and in this episode he's here to talk about Medication, one of the pillars of the Overcoming MS Program. Specifically, Aaron goes into detail on a wide range of disease modifying therapies (DMTs) for MS, as well as discussing when people should start taking DMT's, and what they should consider before they do so. There's lots of useful information in this episode about many different DMT options – we hope you find it useful in making the right decisions for you. Let us know what you think! Watch this episode on YouTube here. Keep reading for the key episode takeaways. Topics and Timestamps: 01:21 What are the medication choices for people with MS and how have they improved? 02:39 When should I start a DMT? 04:30 What should I consider when choosing a drug? 07:08 Alemtuzumab (Lemtrada) 11:14 Cladribine (Mavenclad) 15:05 Fingolimod (Gilenya) 17:13 Mitoxantrone (Novantrone) 18:39 Natalizumab (Tysabri) 21:42 Ofatumumab (Kesimpta) 25:01 Ocrelizumab (Ocrevus) 28:58 Ozanimod (Zeposia) 30:35 Rituximab (Rituxan, MabThera, and Truxima) 32:34 Siponimod (Mayzent) 34:59 Avonex/ Betaferon/ Refib/ Extavia 37:49 Glatiramer Acetate (Copaxone) 40:07 Dimethyl Fumarate (Tecfidera) 42:38 Diroximel Fumarate (Vumerity) 43:46 Plegridy 44:45 Ponesimod (ponvory) 45:41 Teriflunomide (Aubagio) 50:14 Low-dose Naltrexone 52:07 BTK inhibitors Want to learn more about living a full and happy life with multiple sclerosis? Sign up to our newsletter to hear our latest tips. More info and links: Dr Boster was on six previous Living Well with MS episodes: S1E11: Making the Right Medication Choices S2E17: Lifestyle Choices and Their Impact on MS S3E43: Let's Talk About Sex (and MS) S5E5 Webinar highlights from Ask Aaron with Dr. Aaron Boster S5E36 Webinar Highlights: Ask a Neurologist with Dr Aaron Boster S6E19 Webinar Highlights: Ask a Neurologist with Dr Aaron Boster Check out Dr Boster's popular YouTube channel covering all aspects of MS New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.
Welcome to Living Well with MS, the podcast that empowers you to take control of your health and wellbeing. Today we're thrilled to welcome Yvette Sargood as our guest! Yvette is an Overcoming MS facilitator and a meditation teacher who lives with MS and follows the Overcoming MS program. In this fascinating episode, Yvette talks to Geoff about meditation and mindfulness, as well as her personal journey with the MS Program, including disclosing her diagnosis to her employer and how she overcame her chocolate cravings! There's lots of useful information and tips in this episode (including a discussion on chocolate replacements!) We hope you enjoy it – let us know what you think! Watch this episode on YouTube here. Keep reading for the key episode takeaways. Topics and Timestamps: 01:18 Yvette's MS and Overcoming MS journey 07:05 The progress made on DMTs and discrimination since the 1990s 09:01 The benefits to starting the Overcoming MS program even long after diagnosis 11:26 The decision to start a disease modifying therapy 14:59 Her difficulties in adopting the Overcoming MS program 16:27 Overcoming her chocolate cravings and chocolate replacements 18:51 Maintaining a healthy weight on the Overcoming MS program 20:23 The benefits of following the Overcoming MS program 22:54 Disclosing a multiple sclerosis diagnosis to your employer 26:01 Becoming an Overcoming MS facilitator 27:46 What is mindfulness and why is it important for people with MS? 32:53 Misconceptions about meditation and stress reduction 35:42 Tips for people new to the Overcoming MS program Want to learn more about living a full and happy life with multiple sclerosis? Sign up to our newsletter to hear our latest tips. More info and links: Download the Headspace app for meditation Learn more about Disease Modifying Therapies for MS Listen to a podcast featuring OMSer chef Read Yvette's article on executives and disability Learn more about mindfulness expert Jon Kabat-Zinn Join a mindfulness course with Yvette through MS-UK Become an Overcoming MS volunteer To take part in the next Pathway to Overcoming MS course email events@overcomingms.org New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.
Welcome to Living Well with MS, the podcast that empowers you to take control of your health and wellbeing. Today we're sharing the highlights from our ‘Ask Aaron' webinar, recorded in front of a global audience, with the incredible Dr Aaron Boster. Dr Boster is a board-certified neurologist who specialises in MS, and we're delighted to have him answering a huge range of questions from our community! From medications to MRI's and pregnancy to cold showers, Dr Boster gave us so many brilliantly informative answers - we hope you find this episode really useful. Let us know what you think! Watch this episode on YouTube here. Keep reading for the key episode takeaways. Topics and Timestamps: 01:49 Defining benign MS 05:05 How to get the most out of your time with your neurologist 09:32 The DMTs that help with brain atrophy 09:46 MRI's as a way to show the rate of brain atrophy 18:20 Aubagio for secondary progressive MS 22:11 The future of Ocrevus dosing guidelines and becoming pregnant on ocrelizumab 26:31 Treating MS-relating dystonia 28:37 Treatments for MS-related bladder dysfunction 35:15 Low-dose Naltrexone for MS 39:00 The benefits of cold showers 39:38 Immune reconstitution therapies 43:22 Managing MS with diet and exercise To join us live for the next webinar or watch the original presentation head to our website overcomingms.org More info and links: Dr Boster was on five previous Living Well with MS episodes: S1E11: Making the Right Medication Choices S2E17: Lifestyle Choices and Their Impact on MS S3E43: Let's Talk About Sex (and MS) S5E5 Webinar highlights from Ask Aaron with Dr. Aaron Boster S5E36 Webinar Highlights: Ask a Neurologist with Dr Aaron Boster Check out Dr Boster's popular YouTube channel covering all aspects of MS New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.
Moderator: Melinda Magyari (Copenhagen, Denmark)Guest: Thomas Berger (Vienna, Austria)Melinda Magyari and her guest Thomas Berger talk about how aging affects MS progression and management, focusing on immunosenescence's impact on the immune response and DMT effectiveness. They cover the rise of comorbidities in older MS patients, the challenges of using DMTs over age 55, the lack of clinical trials for this age group, and share lifestyle tips to improve quality of life and health outcomes.
CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/comparative-efficacy-subq-vs-intravenous-dmts-in-alzheimers-disease/26347/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.
As Harvard Fellow Dr. Nara Michaelson treated women who had been recently diagnosed with MS, she recognized they shared characteristics that she had observed in victims of violent domestic abuse. Dr. Michaelson's observation led her to write The Unraveling, an essay that highlights the fear that can accompany the uncertainty of living with MS. Dr. Michaelson joins me to discuss the experiences that led to her award-winning essay and to share resources that can help maintain your emotional health and well-being in a good place when you're living with MS. We're also sharing the details about BEAT-MS, a clinical trial that will compare autologous hematopoietic stem cell transplantation (AHSCT) with high-efficacy disease-modifying therapies when it comes to reducing or eliminating MS relapse activity. And we'll let you know how to find out if you could be a potential participant in this important clinical trial. We'll tell you about the FDA approval granted to Abata Therapeutics to conduct a Phase 1 clinical trial of ABA-101, their experimental therapy for progressive MS. We're sharing news about the Federal Trade Commission's newly released report on Pharmacy Benefit Managers. (And we'll tell you why this matters to every person in the United States who takes a prescription medication) And we'll tell you about Take Charge, a new virtual program from Can Do MS that you can participate in at no cost! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: The Unraveling :22 BEAT-MS clinical trial compares AHSCT with high-efficacy DMTs 1:58 FDA clears ABA-101 for Phase 1 clinical trial 5:17 FTC is turning its focus to Pharmacy Benefit Managers 6:55 Can Do MS offers new Take Charge virtual program 11:47 Dr. Nara Michaelson discusses her award-winning essay, The Unraveling 13:23 Share this episode 29:15 Next week: Dr. Riley Bove discusses how digital technology has become a game-changer in diagnosing, treating, and managing MS 29:35 Have you downloaded the free RealTalk MS app? 29:55 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/359 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com The Unraveling https://neurology.org/doi/10.1212/WNL.0000000000209492 BEAT-MS Clinical Trial https://beat-ms.org RealTalk MS Episode 205: A Potentially Transformational Therapy for Progressive MS with Samantha Singer and Dr. Richard Ransohoff https://realtalkms.com/205 FTC Report -- Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies https://ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf REGISTER for Take Charge https://cando-ms.org/event/take-charge-young-and-newly-diagnosed Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 359 Guests: Dr. Nara Michaelson Privacy Policy
CME credits: 1.00 Valid until: 25-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/on-the-clinic-floor-addressing-the-most-critical-questions-of-frontline-clinicians-in-multiple-sclerosis-management/16629/ The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.=
Warrior: Christian AI: Multiple Sclerosis HSCT: 11/3/23 at the Tom Baker Cancer Center in Calgary Superpower: body awareness What is your capacity for listening to your body? How well do you fare through complications? How comfortable are you with looking inward? After the numbness and tingling in his legs restricted his capacity to walk in the course of just a few weeks, Christian was quickly diagnosed after finding the right doctor who knew what his symptoms were indicating. After cycling through a variety of disease-modifying therapies over the course of seven years, Christian continued relapsing. After the humbling and terrifying experience of being wheelchair-bound for a few months in December of 2022, Christian switched DMTs again and after it didn't stop new lesions, he was eventually referred for HSCT in Calgary in June of 2023. Tune in to learn more about the circumstances that led Christian to pursue HSCT in Calgary, and how he fared through the myeloablative protocol, including complications and resolutions. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
Welcome to Living Well with MS, where we are pleased to welcome Dr Stefano Pluchino as our guest! Dr Pluchino is a Professor of Regenerative Neuroimmunology at Cambridge University and has been researching stem cell therapy for progressive MS. In this episode, Dr Pluchino speaks to Geoff about what advanced cell therapy is, the success of his phase one trial and what the future of DMTs looks like indicating what people with MS may experience. Watch this episode on YouTube here. Keep reading for the key episode takeaways. Topics and Timestamps: 01:31 Dr Pluchino's background and research into stem cell therapy for progressive MS. 02:52 The difference between types of MS. 05:09 Navigating DMT options for progressive MS. 08:40 Dr Pluchino's advanced cell therapy research trial: The success of phase one and plans for phase two. 21:05 How advanced cell therapy compares to HSCT or bone marrow transplants. 26:02 What it means for the future of DMTs. 33:39 How you can be part of groundbreaking MS research and trials. Selected Key Takeaways: There are nuances in types of MS beyond ‘relapsing' or ‘progressive'. 04:23 "It is becoming more complex between active and non-active types of primary and secondary progressive MS where activity is attributed to other episodes. Clinical episodes of disease or radiologically evident episodes of disease, which can be identified by the use of contrast agents at the time of the MRI. So, they are very complex very heterogenous types of disease, with or without activity, which inevitably undergo accumulation of neurological deficits.” The next generation of DMTs will target progression rather than relapses. 06:39 “What's becoming very interesting is that [over the last] few years, there is a general worldwide consensus that progressive MS is becoming and has become a clinical unmet need. The old MS world is concentrating on financing, funding and efforts towards stopping MS through the development of a new generation of DMDs which will eventually target progression rather than relapses.” The future of advanced cell therapy research will look at remyelination, reduction of inflammation and neuroprotection. 19:10 "There is space for assessing whether a proportion of the injected cells [can] differentiate in vivo into new myelin-forming cells. There is a space to assess whether some of the cells [can] increase the survival of neurons in the brain. There is space to assess whether the transplanted cells [can] reduce the type of inflammation which characterises progressive MS, which is what we call a smouldering inflammation. These highly diffuse homogeneous, low-level activations of microglia (immune cells of the central nervous system) and astrocytes (star-shaped cells that hold nerve cells in place) might be reduced by means of advanced cell therapy and the reason why I am specifically alluding to these three major biological mechanisms of disease, remyelination, reduction of inflammation and neuroprotection is because we have managed to identify each of these mechanisms in clinically relevant animal disease models in the last 25 years. So, there is [an] expectation that a clinical trial designed in a way that will allow us to establish the efficacy of the treatment will reveal what we have established already in one of these models.” Want to learn more about living a full and happy life with multiple sclerosis? Sign up to our newsletter to hear our latest tips. More info and links: Video on Early-stage stem cell therapy trial shows promise for treating progressive MS Dr Pluchino's website Dr Pluchino's bio If you have progressive MS you may be eligible for the Octopus trial Learn about HSCT from Professor Richard Burt in Season 5 Episode 25 Read about the Shinya Yamanaka and John Gurdon'a Nobel Winning iPSC technology Find out more about the latest research in progressive MS from the International Progressive MS Alliance New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.
Welcome to Living Well with MS. In this episode, we are sharing the highlights from one of our ‘Ask Aaron' webinars, where neurologist, Dr Aaron Boster, answers questions about MS from the community. In this episode, Dr Boster covers a range of topics, including heat intolerance, when to start a DMT and his tips for self-managing MS. You can watch the original webinar here. Keep reading for the key episode takeaways. Topics and Timestamps: 02:13 Considerations for changing to a less stressful job and stronger DMTs. 05:09 Talking to clinicians about stress. 06:25 Hyperbaric oxygen therapy. 08:11 Stem cell transplants for PPMS. 10:35 Tysabri during pregnancy and breastfeeding. 12:23 MS and Stroke. 13:52 MRI showing brain cysts. 16:57 Betaferon and slow progression. 19:45 Changing from Tysabri to Ocrevus. 21:41 Vertigo. 23:05 Ampyra for walking, spasticity, and nerve pain. 25:50 Types of inflammation. 28:05 Anesthetic or epidural and MS. 30:15 B-cell depletion therapy and allergies. 31:17 Tips for self-managing MS. 37:42 Heat intolerance. 40:30 When to start on a DMT. 41:22 Ocrevus and low lymphocyte levels. 43:40 Diet and MS. 48:50 Nausea as an MS symptom. 51:30 CBD for MS. 52:45 Bursitis and MS. 53:36 Choosing a DMT and considering side effects. 55:16 Invisible illness in an ableist world. Selected Key Takeaways: Exercise as part of your daily lifestyle 34:42 “Exercising as part of a lifestyle means that if you do it, you're not rewarded. There's no reward for doing something as part of your lifestyle and if you don't do it, there's no punishment - you're not sent to the naughty corner. So, for example, I have a lifestyle of brushing my teeth. I don't tweet about it. I don't make YouTube videos about it. I don't even talk about it when I get to work. It's just something I do every morning and if I happen to forget to brush my teeth before I head off to the office, I'll run upstairs and do it. This is part of my lifestyle. So, I need people impacted by MS to exercise as part of their lifestyle.” Plan your day to minimise symptoms like heat intolerance 39:43 “We can conserve energy during those times when it's really hot out. Whereas I would normally encourage a patient to park at the back of the parking lot to get their steps in. If it's the middle of the day, [walking that far is] going to sap all your energy so that when you get to the grocery store you can't shop, that doesn't really work very well, does it? And so that's an example where we would have someone drop us off at the threshold of the grocery store so that you can be successful in your shopping.” Be brave in using mobility aids and seeking accommodations. 57:27 “I tell people who are embarrassed by their cane, ‘Don't you dare be embarrassed by your cane, a cane is a sign of intelligence.' A person with a cane would like to not fall. So, when a little boy is walking with [his] mum, and says, ‘Mummy, why is she using a cane?' That's an opportunity for the mother to say, ‘Well, she doesn't want to fall, she has a problem with her leg and the cane helps her.' It normalises it. So, one of the things that we need to do is to be brave. I'll remind you of the definition of bravery, ‘doing something despite being scared'. The second thing is, I want you to be very selfish. You need to be selfish; you live your life once. You're not living your life so some stranger, you don't know, thinks nice polite things about you.” Want to learn more about living a full and happy life with multiple sclerosis? Sign up to our newsletter to hear our latest tips. More info and links: Watch the original webinar here. Dr Boster was on three previous Living Well with MS episodes: S1E11: Making the Right Medication Choices S2E17: Lifestyle Choices and Their Impact on MS S3E43: Let's Talk About Sex (and MS) Check out Dr Boster's popular YouTube channel covering all aspects of MS. New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.
All people with MS should discuss taking a disease modifying therapy (DMT) with their MS provider. When offered, most people with MS choose to take them. Fortunately, we now have several DMTs that slow the course of MS. These medications have all been proven to benefit people with MS in well-designed large studies. Because DMTs, like any medication, come with risks, people with MS must decide for themselves. Join Dr. Kayla Martin to better understand your DMT options.
This week, we're sharing more from the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting. What if we could identify MS before anyone experienced any of the typical clinical symptoms? Would treating that person with a high-efficacy disease-modifying therapy prevent the clinical symptoms of MS from even developing? Those are the questions that make the study of the MS prodrome so fascinating and important. At the joint ECTRIMS-ACTRIMS meeting, I met up with one of the foremost experts on the prodromal phase of MS, Dr. Helen Tremlett, who shared an update on what she's continuing to learn about the MS prodrome. We'll also tell you about Dr. Jeffrey Huang's work in developing an experimental drug that may stop MS progression and stimulate remyelination. We're sharing a report from Deloitte that analyzes the economic impact of the pandemic gap for people living with MS in Canada. We'll tell you about the results of a study that show lower-efficacy disease-modifying therapies can lead to faster disability accumulation. You'll hear about the work being done to deliver Ocrevus in a subcutaneous injection. And we'll tell you what happened that caused a study focused on stopping your DMT if your MS was stable to be called off. I had the good fortune of speaking with several research presenters at the joint ECTRIMS-ACTRIMS meeting, and I'll be releasing those bonus ECTRIMS Extra Conversations all week long. It's an opportunity for you to listen in to my conversations with some of the top MS research and clinical experts in the world. Be sure to look for these conversations throughout this week! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: More from the largest MS research conference in the world :22 Don't miss ECTRIMS Extra Conversations all week long! Georgetown University researchers develop a drug that may stop MS progression and stimulate remyelination 1:20 The cost of the pandemic gap for people living with MS in Canada 3:10 Study shows that lower-efficacy DMTs can lead to faster disability accumulation 7:12 Clinical trial demonstrates that subcutaneous formulation of Ocrevus is safe and effective 10:47 Your MS stable, no relapses for at least 5 years. Can you stop your DMT? 12:33 Dr. Helen Tremlett explains how understanding the MS prodrome can change the future of MS treatment 15:49 Share this episode 21:26 Have you downloaded the free RealTalk MS app? 21:47 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/321 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com REPORT: The Socioeconomic Cost of, and Impact of, COVID-19 on Multiple Sclerosis in Canada https://mscanada.ca/sites/default/files/documents/2023-10/deloitte-covid-19-impact-english.pdf ECTRIMS PRESENTATION: Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase 1b Dose-Finding OCARINA 1 Study https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.congrex/abstracts_ectrims2023/148349.pdf ECTRIMS PRESENTATION: Discontinuation of First-Line Disease-Modifying Therapy in Stable MS (DOT-MS): An Early-Terminated Multicenter Randomized Controlled Trial https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.congrex/abstracts_ectrims2023/146784.pdf Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 321 Guest: Dr. Helen Tremlett Privacy Policy
Welcome to Living Well with MS, where we are pleased to welcome Melanie Lown as our guest. Melanie is a mindfulness teacher, has an M.A. in Psychology, and follows the Overcoming MS Program. She talks to Geoff about her MS diagnosis, the power of mindfulness and the importance of self-compassion. Watch this episode on YouTube here. Topics and Timestamps: 01:30 Melanie's introduction and MS diagnosis. 03:58 Balancing self-advocacy with compassion for healthcare professionals. 07:07 Using a diagnosis to discover your purpose. 09:48 Discovering Overcoming MS. 12:02 Our lived experience is as valid as datasets. 13:29 DMTs and COVID. 16:31 The growing popularity of mindfulness in Western medicine. 21:45 Meditation physically changes the brain. 23:33 Depression and spiritualism are opposite sides of the same neural pathway. 27:54 The awakened brain vs. the achieving brain. 29:39 Activating the parasympathetic nervous system with self-compassion. 33:39 Emotions are not ‘good' or ‘bad'. 35:44 Mindfully choosing your healthcare team and treatment. 42:22 Tips to incorporate mindfulness into your lifestyle. 47:54 Non-judgmental awareness. More info and links: Visit Melanie's Website or follow her on Instagram: @welcometothemat. Melanie's Recommended Meditation teachers and guides: Vinny Ferraro Amanda Gilbert Elisha Goldstein Tara Branch Davidji Insight Timer New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Melanie's Recommended Books: The Awakened Brain by Dr. Lisa Miller Self-Compassion by Kristin Neff How to Change Your Mind by Michael Pollan Radical Acceptance by Tara Brach Cured by Jeffrey Rediger Learned Hopefulness by Dr. Dan Tomasulo Melanie's Recommended Scientific Articles: Fredrickson, B. L., & Losada, M. F. (2005). Positive affect and the complex dynamics of human flourishing. American psychologist, 60(7), 678. Miller, L., Bansal, R., Wickramaratne, P., Hao, X., Tenke, C. E., Weissman, M. M., & Peterson, B. S. (2014). Neuroanatomical correlates of religiosity and spirituality: a study in adults at high and low familial risk for depression. JAMA psychiatry, 71(2), 128-135. Miller, L., Wickramaratne, P., Gameroff, M. J., Sage, M., Tenke, C. E., & Weissman, M. M. (2012). Religiosity and major depression in adults at high risk: a ten-year prospective study. American Journal of Psychiatry, 169(1), 89-94. Portnoff, L., McClintock, C., Lau, E., Choi, S., & Miller, L. (2017). Spirituality cuts in half the relative risk for depression: Findings from the United States, China, and India. Spirituality in Clinical Practice, 4(1), 22. Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.
Barbara S. Giesser, MD, FAAN, FANA, is an internationally recognized clinician and award-winning educator who has specialized in the care of persons with Multiple Sclerosis since 1982. Her approach to the diagnosis and management of persons with MS combines advanced diagnostics and a personalized medication plan for each patient with an emphasis on integrating lifestyle and wellness strategies into the neurologic treatment plan. Learn about disease modifying therapies for the treatment of Multiple Sclerosis in this PNI Minute.For more information: 310-582-7613 | pacificbrainhealth.org
Which is the “right” treatment plan for you to manage multiple sclerosis? There are so many disease modifying drugs (DMTs) and they all have pros and cons. You just want help deciding which is the right one for you. You're not alone. Today's episode is created to help prepare you for this discussion with your doctor. This isn't medical advice or the details of pharmaceutical drugs. This is about learning what to ask and how to collaborate with your doctor in reaching the best plan for you.
The annual economic burden for the nearly 1 million people living with Multiple Sclerosis in the U.S. is, wait for it … $85.4 billion. That's billion. With a “b.” The $85.4 billion, according to a report from the National Multiple Sclerosis Society, is the total cost to all of society, which includes people living with MS; employers; health insurers; and federal, state and local government. Join us for this episode of A Couple Takes on MS Podcast as we bring awareness to the high-cost realities of what it takes to live with MS and a disability. The reality is that there is nothing cheap about living with MS. Whether it's having to pay for a hotel room while visiting friends and family because their homes aren't handicapped accessible, covering costs for purchasing and maintaining a power wheelchair and accessible van, or all the added supplements and heath care products, life with MS is expensive. And we haven't even mentioned the astronomical costs for disease-modifying therapies. How astronomical? As of February 2022, the median annual price of the brand MS DMTs is close to $94,000. Six of the MS DMTs, all on market since 2009 or earlier, have increased in price more than 200% and nine DMTs are now priced at over $100,000. The sad thing is that the aforementioned figures are from studies released last year, so Lord knows how much annual increases and inflation have ballooned the costs related to having MS. And, as we note in our podcast, we aren't talking about this to complain or go on a rant; rather, it's to increase awareness about the seemingly unfair financial facts of life with MS that so many of the nearly 1 million people in the U.S. living with the disease are just expected to deal with and accept. Here are the links to the articles we discussed: • Cost of Multiple Sclerosis • The Economic Burden of Multiple Sclerosis in the United States
Welcome to Living Well with MS. In this episode, we are delighted to welcome neurologist, Professor Stephen L. Hauser as our guest. Professor Hauser has been researching MS since the 1970s, and his team's research led to the development of the disease-modifying therapy ‘Ocrevus'. He talks to Geoff about the future of DMTs for MS, what autoimmunity is, and how he and his team developed one of the most world-renowned MS DMTs. Questions and Timestamps 01:45 Can you introduce yourself and tell us about your work? 04:23 What is autoimmunity and how does it relate to MS and inflammation? 06:37 Are some people more prone to develop autoimmune conditions? 10:11 How can a person get the most out of the time they have with their neurologist? 14:01 The benefits of participating in a clinical trial. 16:01 How is MS similar or different from other brain conditions? 20:11 Is there a role of infection in brain diseases like MS? 23:10 The role of hygiene in autoimmunity. 25:40 Book excerpt and how Ocrevus was developed. 32:53 What's next in B-cell research and MS? 37:58 What tips do you have for lifestyle modifications for people who have MS? More info and links: Read more about Professor Hauser from the American Brain Foundation Read The Face Laughs While the Brain Cries: The Education of a Doctor Read the key episode takeaways and Professor Hauser's bio New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episode here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. If you enjoy this podcast and want to support the ongoing work of Overcoming MS, you can leave a donation.
In this episode, we are sharing the highlights from our webinar 'Women's Health' with Dr. Jonathan White and Professor Helen Reese Leahy. Dr. Jonathan White is an Obstetrician and Gynecologist, and the Overcoming MS Medical Advisor. Helen lives with primary progressive MS and follows the Overcoming MS Program. They discuss how MS impacts women's health and how the Overcoming MS Program can best support women's health. This webinar was recorded as part of our Finding Hope with Overcoming MS webinar series. You can watch the whole webinar here or the podcast highlights on YouTube here. Keep reading for the key episode takeaways and bio information. Topics and Timestamps 00:56 The history of MS research with women (Helen) 08:15 Reproductive health and MS (Jonathan) 26:14 The Overcoming MS Program supports every aspect of women's health (Helen) 34:51 Hormone replacement therapy (HRT) (Jonathan) 47:41 Bladder issues with MS and menopause (Jonathan and Helen) Selected Key Takeaways More research is needed to understand menopause's effect on MS "The age group with the highest number of people with MS, both men and women, is now 55-64. So, if you think about [that] within the general MS population, that's obviously a very large number of women who are either menopausal or postmenopausal. But very, very few women over 50 are recruited for MS research trials. So, the effects of menopause on the lives and health of women with MS, in general, but also our response to DMTs, are very under-researched.” Inflammation can worsen as we age "‘Inflammageing' is a fascinating term, which essentially [means] the inflamed pro-inflammatory state that people exhibit as they get older. A lot of the conditions we develop at an older age are actually due to increases in inflammation. Cardiovascular disease would be a prime example of that. We think that ‘Inflammageing' certainly has a role in this mixed bag of MS and menopause, and of course, the obvious one to look at will be oestrogen deficiency. Is HRT beneficial if you have MS? There is some evidence to say that it is. But again, none of those studies are prospective or randomised control studies. Generally speaking, it's not recommended to take HRT just by virtue of having MS to protect yourself. But there's certainly no reason not to [take it] because you have MS [and menopause] and in fact, it may be beneficial. So, if you are struggling with the hot flushes, the night sweats or your urinary symptoms have suddenly got much worse, you're suffering from vaginal dryness, then this is definitely a conversation that you should be having." Bladder issues are common with MS and menopause "With MS in both males and females, we think up to between 50% and 70% of people will have bladder dysfunction due to MS. That usually affects the nerves supplying the muscle, the detrusor muscle in the bladder wall, and makes it very irritable, so it tends to be an overactive or urge problem with MS. That's also very common post-menopause, and the mechanism isn't entirely the same, but it does share a bit, and part of it is certainly to do with oestrogen deficiency." More Info and Links: Watch the original webinar Listen to Dr. Jonathan White's podcast episodes on Season 1 Episode 2, Season 2 Episode 19, Season 3 Episode 32, the 100th Episode, and Season 4 Episode 64 Read the paper‘Effects of Menopause in Women with Multiple Sclerosis: An Evidence-Based Review' Read ‘Does menopause influence the course of MS?' Visit the Royal College of Obstetricians, Gynecologists' women's health hub The British Menopause Society The Women's Health Concern Listen to Dr. Rachael Hunter discuss the 3Ps on S4E67 Listen to Helen's podcast episode about Primary Progressive MS New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook https://www.facebook.com/OvercomingMS/ Instagram https://www.instagram.com/overcomingms/ YouTube https://www.youtube.com/overcomingms Pinterest https://www.pinterest.com/overcomingms/ Website https://overcomingms.org/ Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS. Dr. Jonathan White's Bio Career: Jonathan went to the University of Glasgow Medical School, graduating in 2008 (MBChB). He completed a further five years of training in Obstetrics and Gynecology and is a member of the Royal College of Obstetricians & Gynecologists (MRCOG). He works at the Causeway Hospital, Coleraine and has a special interest in early pregnancy and recurrent pregnancy loss. In April 2022, Jonathan was awarded “Doctor of the Year” at the inaugural Northern Ireland Health and Social Care Awards. He contributed to the ‘Overcoming Multiple Sclerosis Handbook: Roadmap to Good Health', by writing the chapter about medication. Overcoming MS and personal life: Jonathan was diagnosed with RRMS in October 2015 and has been following the Overcoming MS Program ever since. Dr. White assists Overcoming MS as a medical advisor and event facilitator. He lives on the North Coast of Northern Ireland, is married to Jenny and father to Angus and Struan. His interests include the great outdoors, cycling and running (reluctantly), reading, rugby, film and spending time with his family. Professor Helen Rees Leahy's bio: MS and Overcoming MS Helen was diagnosed with Primary Progressive MS in 1997 when she was 37 years old. Being ineligible for any Disease Modifying Treatment (DMT) within the UK National Health Service, she began to explore holistic approaches to managing her condition. She discovered Overcoming MS in 2008 and has followed the Program ever since. She was previously a Trustee for Overcoming MS. Personal life and career Helen lives in Conwy, a small, medieval town in North Wales. In 2017, she took medical retirement from the University of Manchester where she was a Professor in the Department of Art History and Cultural Practice. As an Emerita Professor, Helen continues to research and teach doctoral students. She also spends time hand-weaving and learning Welsh, the language of her ancestors.
Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD
2023 marks 30 years since the very first MS disease-modifying therapy received FDA approval. To say that changed everything would be an understatement. Two of the top MS experts in the world have published a reflection, looking back at how MS research and treatment has progressed over the past 30 years and looking ahead at the challenges that remain in solving the riddle of MS. Joining me this week are the authors of that reflection, Dr. Fred Lublin and Dr. Stephen Krieger. Dr. Lublin participated in the development of the very first disease-modifying therapy approved for treating MS and, since that time, he has been involved in the development of nearly all of the DMTs available today. Dr. Krieger has developed a game-changing theory that MS is a single disease that evolves along a continuum, rather than the four separate categories that neurologists have used to describe MS for the past couple of decades. We'll also introduce you to The Community Review of MS Research Committee. We'll share what very well may be the single most important development to come out of the Pathways To Cures Global Summit. We'll tell you about the outcome of a study that may point to a potential MS treatment for women that has also been shown to trigger myelin repair. We'll explain the method for accurately measuring remyelination that was just recently confirmed by a UCSF research team. And we'll tell you where you can catch the video replay of the webcast that was live-streamed from last month's International Progressive MS Alliance Scientific Congress. We have a lot to talk about! Are you ready for RealTalk MS??! I'm back from the Community Review of MS Research Committee meeting :22 This Week: 30 Years Later....looking back (and ahead!) 4:08 The first-ever Global Research Strategy Framework has been announced 5:26 Don't miss the video replay of the webcast that was live streamed from last month's International Progressive MS Alliance Scientific Congress 2:55 A study shows that the hormone estriol reduces MS severity and promotes myelin repair 9:54 A UCSF research team has developed a method of accurately measuring remyelination 13:16 Dr. Fred Lublin and Dr. Stephen Krieger review the progress that's been made since the approval of the first MS disease-modifying therapy and they look ahead at the challenges that remain in solving the riddle of MS 17:23 Share this episode 30:08 Have you downloaded the free RealTalk MS app??? 30:27 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/305 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com RealTalk MS Episode 297: The Pathways To Cures Global Summit (Part 1) https://realtalkms.com/297 RealTalk MS Episode 298: The Pathways To Cures Global Summit (Part 2) https://realtalkms.com/298 Video Replay: Ending MS Progression: Research Advances That Could Lead to Breakthrough Treatment https://www.youtube.com/watch?v=p9OQ_hvVpfA STUDY: Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol https://sciencedirect.com/science/article/pii/S0023683723001320?via%3Dihub RealTalk MS Episode 189: Research on Sex Differences in MS Leads to Potential Treatment Options with Dr. Rhonda Voskuhl https://realtalkms.com/189 STUDY: MWF of the Corpus Callosum Is a Robust Measure of Remyelination: Results from the ReBUILD Trial https://pnas.org/doi/10.1073/pnas.2217635120 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 305 Guests: Dr. Fred Lublin and Dr. Stephen Krieger Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy
Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors for the treatment of MS; and Identify patients who may benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors for the treatment of MS; and Identify patients who may benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors for the treatment of MS; and Identify patients who may benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer's disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients' needs in consultation with other members of the healthcare team.
Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer's disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients' needs in consultation with other members of the healthcare team.
To tell or not to tell. When it comes to disclosing your MS to friends and family, that is the question. Choosing when to disclose and to whom to disclose is a deeply personal decision. Joining me to talk about some of the risks and benefits of disclosing your diagnosis is Dr. Victoria Leavitt, a clinical neuropsychologist, researcher, and assistant professor of neuropsychology at Columbia University. Well also tell you about a just-announced collaboration to develop an Epstein-Barr Virus vaccine (and we'll tell you why that could be a huge step toward ending MS forever!) We're sharing the details behind the MS International Federation's application to have three MS disease-modifying therapies added to the World Health Organization's list of essential medicines. We'll tell you how a study that tested a fall prevention program for people living with MS who used a wheelchair or scooter full-time may have failed...and yet succeeded. We're sharing the results of a study that set out to determine whether people over 50 who were living with MS were increasing their use of health care services because of their MS or simply because they were aging. And we'll tell you about a study that focused on the psychosocial impact of MS on children who had a parent living with MS. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Disclosing Your MS :22 Merck teams up with ModeX Therapeutics on an EBV vaccine 1:10 The MSIF applies to have 3 DMTs added to the WHO list of essential medicines 3:22 STUDY: A fall prevention program for people with MS who are full-time wheelchair or scooter users 6:47 STUDY: Health care usage among people over 50 who are living with MS 9:33 STUDY: The psychosocial impact of MS on children with a parent living with MS 12:02 Dr. Victoria Leavitt discusses the risks and rewards associated with disclosing your MS to friends and family 15:24 Share this episode 32:35 Have you downloaded the free RealTalk MS app? 32:55 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/290 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Editorial: Toward Equitable Access to Treatment for Multiple Sclerosis https://thelancet.com/action/showPdf?pii=S1474-4422%2823%2900041-8 STUDY: Online Delivery of the Individualized Reduction of Falls Intervention for Persons with Multiple Sclerosis Who Use a Wheelchair or Scooter Full-Time: A Pilot Study https://meridian.allenpress.com/ijmsc/article/25/2/82/491441/Online-Delivery-of-the-Individualized-Reduction-of STUDY: Outcomes and Health Care Service Use in Adults 50 Years and Older With and Without Multiple Sclerosis https://meridian.allenpress.com/ijmsc/article/25/2/56/486192/Outcomes-and-Health-Care-Service-Use-in-Adults-50 STUDY: The Psychosocial Impact of Parental Multiple Sclerosis on Children and Adolescents: A Systematic Review https://meridian.allenpress.com/ijmsc/article/25/2/63/487609/The-Psychosocial-Impact-of-Parental-Multiple Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 291 Guest: Dr. Victoria Leavitt Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy
Dr. Shuvro Roy talks with Dr. Matilde Inglese about comparing stem-cell transplants to DMTs in patients with Secondary Progressive MS. Read the related article in Neurology®.
Welcome to the Neoborn And Andia Human Show's electrifying new episode! This week, we tackle some hard-hitting topics that'll make you want to tune in and listen up. First up, we discuss why rolling over to oppressors and overlords is a big no-no, and how acting out of fear can lead to suffering and ghettos. We also delve into the importance of belonging and how Gen Z can change their ways for the better.Next, Professor Andia enlightens us on hedonism and the power of DMTs and magic mushrooms. We then review a great live performance by The Unlimited Star, followed by a discussion on books being banned for no apparent reason and the absurdity of wrongthink Britain.We also uncover the shocking truth behind Zantac by GlaxoSmythKline and how it has been killing thousands of people for 40 years with its potent carcinogen. Our conversation then shifts to the loss of freedom of speech and religion in Canada, and how China is reshaping the country.To lighten the mood, we have a quick round of Battle of Jokes, followed by a discussion on the serious problems of Gen Z and how troubles in relationships can lead to wars. What's more, you may hear a fresh take on an Emily Dickinson's poem in a newer gown.Tune in to the Neoborn And Andia Human Show for a thought-provoking, entertaining, and electrifying episode that'll leave you wanting more! Don't miss out on the musings and sketches of these Two Purple Rabbits, Neoborn Caveman and Andia.Supporting Purple Rabbits!...................................... Hosted on Acast. See acast.com/privacy for more information.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Darin Okuda, MD, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more. Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page. Episode Breakdown: 1:20 – Overview of ARISE and conduct of study 4:20 – Potential subgroup responders to dimethyl fumarate 8:10 – Efforts to improve the detection of radiologically isolated syndrome 10:05 – Neurology News Minute 11:55 – Next steps of research following ARISE 16:50 – Closing thoughts on significance of the study This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter Aducanumab's Label Updated to Include Risks on Brain Bleeding Primary Care Physicians Show Greater Confidence in Diagnosing Alzheimer Disease Through DISCERN Skin Test FDA Approves Extended-Release Deutetrabenazine for Huntington Disease Chorea, Tardive Dyskinesia Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE Okuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl fumarate delays multiple sclerosis radiologically isolated syndrome. Ann Neurol. 2023;93(3):604-614. doi:10.1002/ana.26555
Every episode of RealTalk MS features updates and reports about emerging science. And, as you listen, some of you may wonder, 'When will these scientific achievements benefit me? When will these breakthroughs and advancements make their way from the laboratory workbench to the clinic?' That's exactly what the panel of MS experts who comprise the International Advisory Committee on Clinical Trials in MS are proposing in a new framework that leverages what scientists are continuing to learn and re-defines how we talk about MS, research MS, diagnose MS, and treat MS. The new framework being recommended by the committee is broadly outlined in a paper that was published about 8 weeks ago. Joining me to discuss what this proposed framework is all about is the paper's lead author, Professor Tanja Kuhlmann. We're also talking about the new high-efficacy disease-modifying therapy that received its FDA approval last week. We're sharing the details behind the FDA's approval of a Phase 3 clinical trial for Masitinib, an investigational therapy for treating progressive MS. We'll tell you about Abata Therapeutics' first T-cell treatment candidate for treating progressive MS. And you'll hear about the results of a study that compared the outcome of treating people living with secondary progressive MS with autologous hematopoietic stem cell transplantation (aHSCT) versus treatment by disease-modifying therapies. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Experts recommend a new framework for researching, diagnosing, and treating MS :22 FDA approves Ublituximab (Briumvi), an anti-cd20 disease-modifying therapy 1:12 FDA approves Phase 3 clinical trial for Masitinib as a treatment for progressive MS 4:35 Abata Therapeutics announces its first T-cell therapy candidate to treat progressive MS 7:20 Study shows aHSCT more effective than DMTs in treating secondary progressive MS 10:14 Professor Tanja Kuhlmann discusses a new framework for researching, diagnosing, and treating MS 13:51 Share this episode 26:37 Have you downloaded the free RealTalk MS app? 26:57 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/279 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com STUDY: Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis https://nejm.org/doi/full/10.1056/NEJMoa2201904 AB Science https://ab-science.com RealTalk MS Episode 205: A Potentially Transformational Therapy for Progressive MS with Samantha Singer and Dr. Richard Ransohoff https://realtalkms.com/205 STUDY: Hematopoietic Stem Cell Transplantation in People with Active Secondary Progressive MS https://n.neurology.org/content/early/2022/12/21/WNL.0000000000206750 Take the iConquer MS Caregiver Survey https://realtalkms.com/caregiver Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 279 Guest: Professor Tanja Kuhlmann Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy
© 2020-2025 Ivy Podcast Discovery LLC
